How do I install the Endo Paget Early Response Assessment skill?

Run npx skillmds@latest add dromlakhani/endo-paget-early-response-assessment in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Paget Early Response Assessment safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Paget Early Response Assessment?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Paget Early Response Assessment free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Paget Early Response Assessment?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Paget Early Response Assessment by dromlakhani

Name: Endo Paget Early Response Assessment
Rating: 4.5 (4 reviews)
Author: dromlakhani

Endo Paget Early Response Assessment

This skill outlines using short-term changes in bone resorption markers (e.g., serum CTx or urine NTx) before and shortly after bisphosphonate therapy to predict an adequate therapeutic response. It is triggered when there is urgency to control severe symptoms or when Paget’s disease is highly active, prompting rapid efficacy assessment.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Assess early therapeutic response using bone resorption markers

STEP 1 — Gather Information

Collect baseline bone resorption marker (preferably serum CTx or urine NTx) and assess clinical urgency (severe bone pain, neurologic signs, high turnover disease). Also note renal function if using CTx.

STEP 2 — Rule In / Rule Out

Determine if urgency exists (severe symptoms or highly active disease). If yes, proceed to early marker assessment; if not, follow standard monitoring schedule.

STEP 3 — Classify or Stratify

After initiating potent bisphosphonate (e.g., zoledronate 5 mg IV), repeat the same bone resorption marker at short interval (e.g., 3–10 days). Calculate percent change; a substantial decline (≥50% reduction or reaching nadir) predicts adequate response; minimal change suggests inadequate response.

STEP 4 — Decide

If early marker decline is substantial, continue current therapy and plan routine follow‑up; if decline is insufficient, consider treatment escalation, switch to alternative potent agent, or investigate adherence/comorbidities.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on symptoms alone; marker variability requires same assay and timing; avoid using formation markers (ALP, P1NP) for early response; interpret cautiously in renal impairment as CTx may be affected; do not delay urgent treatment awaiting marker results; recognize that markers can fluctuate due to assay variability or concurrent conditions.

Concrete Clinical Example

A 66‑year‑old woman presents with worsening sacral pain and elevated serum CTx (620 pg/mL). Urgency for symptom control leads to IV zoledronate 5 mg. Serum CTx is repeated on day 7 and falls to 260 pg/mL (58% drop), indicating likely adequate response; she continues routine monitoring at 3‑month intervals.

Source: Endocrine Society Clinical Practice Guideline: Paget’s Disease of Bone, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910

---name: endo-paget-early-response-assessmentdescription: This skill outlines using short-term changes in bone resorption markers (e.g., serum CTx or urine NTx) before and shortly after bisphosphonate therapy to predict an adequate therapeutic response. It is triggered when there is urgency to control severe symptoms or when Paget’s disease is highly active, prompting rapid efficacy assessment.---# Assess early therapeutic response using bone resorption markers## STEP 1 — Gather InformationCollect baseline bone resorption marker (preferably serum CTx or urine NTx) and assess clinical urgency (severe bone pain, neurologic signs, high turnover disease). Also note renal function if using CTx.## STEP 2 — Rule In / Rule OutDetermine if urgency exists (severe symptoms or highly active disease). If yes, proceed to early marker assessment; if not, follow standard monitoring schedule.## STEP 3 — Classify or StratifyAfter initiating potent bisphosphonate (e.g., zoledronate 5 mg IV), repeat the same bone resorption marker at short interval (e.g., 3–10 days). Calculate percent change; a substantial decline (≥50% reduction or reaching nadir) predicts adequate response; minimal change suggests inadequate response.## STEP 4 — DecideIf early marker decline is substantial, continue current therapy and plan routine follow‑up; if decline is insufficient, consider treatment escalation, switch to alternative potent agent, or investigate adherence/comorbidities.## Clinical Guardrails / Mimics / PitfallsDo not rely on symptoms alone; marker variability requires same assay and timing; avoid using formation markers (ALP, P1NP) for early response; interpret cautiously in renal impairment as CTx may be affected; do not delay urgent treatment awaiting marker results; recognize that markers can fluctuate due to assay variability or concurrent conditions.## Concrete Clinical ExampleA 66‑year‑old woman presents with worsening sacral pain and elevated serum CTx (620 pg/mL). Urgency for symptom control leads to IV zoledronate 5 mg. Serum CTx is repeated on day 7 and falls to 260 pg/mL (58% drop), indicating likely adequate response; she continues routine monitoring at 3‑month intervals.**Source:** Endocrine Society Clinical Practice Guideline: Paget’s Disease of Bone, Endocrine Society, 2014, DOI:10.1210/jc.2014-2910

Frequently asked questions